Detalles de la búsqueda
1.
Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
J Thromb Thrombolysis
; 37(4): 549-56, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23943338
2.
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Eur Neurol
; 72(3-4): 173-80, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25226868
3.
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.
Medicines (Basel)
; 5(3)2018 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-29933552
4.
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
J Neurol
; 264(12): 2420-2430, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063242
5.
Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
J Neurol Sci
; 370: 263-268, 2016 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27772772
Resultados
1 -
5
de 5
1
Próxima >
>>